Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative diseases that occur either in relatively rare, familial forms or in common, sporadic forms. The genetic defects underlying several monogenic familial forms of AD and PD have recently been identified, however, the causes of other AD and PD cases, particularly sporadic cases, remain unclear. To gain insights into the pathogenic mechanisms involved in AD and PD, we used a proteomic approach to identify proteins with altered expression levels and/or oxidative modifications in idiopathic AD and PD brains. Here, we report that the protein level of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), a neuronal de-ubiquitinating enzyme whose mutation has been linked to an early-onset familial PD, is down-regulated in idiopathic PD as well as AD brains. By using a combination of two-dimensional gel electrophoresis and mass spectrometry, we have identified three human brain UCH-L1 isoforms, a full-length form and two amino-terminally truncated forms. Our proteomic analyses reveal that the full-length UCH-L1 is a major target of oxidative damage in AD and PD brains, which is extensively modified by carbonyl formation, methionine oxidation, and cysteine oxidation. Furthermore, immunohistochemical studies show that prominent UCH-L1 immunostaining is associated with neurofibrillary tangles and that the level of soluble UCH-L1 protein is inversely proportional to the number of tangles in AD brains. Together, these results provide evidence supporting a direct link between oxidative damage to the neuronal ubiquitination/de-ubiquitination machinery and the pathogenesis of sporadic AD and PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dysfunction contributes to neuronal damage and death by several mechanisms, including ER stress and the accumulation of oxidatively damaged proteins, which in the normal brain are usually degraded by the UPS and autophagy to keep their levels low8,50,53,55.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
In the citing paper
“a crucial part of the UPS is oxidatively damaged and dysfunctional in both aMCI and AD brain, namely, ubiquitin carboxyl-terminal hydrolase L-1 (UCH L1)34,55–57.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
In the citing paper
“the failure of oxidatively damaged UCH L1 to perform its function in aMCI and AD brains leads to accumulation of ubiquitinylated proteins, decreased proteasome function, and subsequent accumulation of damaged, aggregated proteins55.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
Citations
Cites
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Roepstorff, P., & Fohlman, J. (1984) · Biological Mass Spectrometry · doi:10.1002/bms.1200111109 · Cited by 2,633
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Oxidant signals and oxidative stress
Finkel, T. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00002-4 · Cited by 1,393
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Methionine residues as endogenous antioxidants in proteins
Levine, R. L., Mosoni, L., Berlett, B. S., & Stadtman, E. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15036 · Cited by 1,041
The Neuron-Specific Protein PGP 9.5 Is a Ubiquitin Carboxyl-Terminal Hydrolase
Wilkinson, K. D., Lee, K., Deshpande, S., Duerksen-Hughes, P., Boss, J. M., & Pohl, J. (1989) · Science · doi:10.1126/science.2530630 · Cited by 871
Research works printed but not linked: 2
- Ischiropoulos, 2003, J. Clin. Invest., 111, 163, 10.1172/jci200317638 · DOI · Paper page
- Wu, 1996, Alzheimer's Res., 2, 163
Cited by
Items 101–200 of 571
Tramutola, A., Di Domenico, F., Barone, E., Perluigi, M., & Butterfield, D. A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2756068 · Cited by 108
“In light of this evidence, the hydrolase activity of HNE-modified UCHL1 was reduced to about 40–80% of nonmodified UCHL1 and was inversely correlated with the degree of modification [46, 69].”
BackgroundInfluentialLee, Y. M., Park, S. H., Shin, D.-I., Hwang, J.-Y., Park, B., Park, Y.-J., Lee, T. H., Chae, H. Z., Jin, B. K., Oh, T. H., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800426200 · Cited by 113
Ferrer, I. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.004 · Cited by 123
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models
Sonnen, J. A., Breitner, J. C. S., Lovell, M. A., Markesbery, W. R., Quinn, J. F., & Montine, T. J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.04.022 · Cited by 113
Emerging Roles of S -Nitrosylation in Protein Misfolding and Neurodegenerative Diseases
Nakamura, T., & Lipton, S. A. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1858 · Cited by 107
“The UPS is apparently impaired in the aging brain.”
InfluentialBi, H.-L., Zhang, X.-L., Zhang, Y., Xie, X., Xia, Y., Du, J., & Li, H. (2020) · Science Advances · doi:10.1126/sciadv.aax4826 · Cited by 106
“5), is a DUB responsible for removing ubiquitin or polyubiquitin from target proteins (7, 8).”
BackgroundRedox proteomics and amyloid β-peptide: Insights into Alzheimer disease
Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105
“Redox proteomics identified that brain-resident UCHL1 is oxidatively modified in FAD (Butterfield et al. 2006b), LAD (Castegna et al. 2002a; Choi et al. 2004; Sultana et al. 2006c), and DS (Di Domenico et al. 2013, 2014).”
BackgroundIs the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?
Teich, A. F., & Arancio, O. (2012) · Biochemical Journal · doi:10.1042/bj20120653 · Cited by 102
Figueiredo-Pereira, M. E., Rockwell, P., Schmidt-Glenewinkel, T., & Serrano, P. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00104 · Cited by 104
The Role of Long Noncoding RNAs in Central Nervous System and Neurodegenerative Diseases
Wei, C.-W., Luo, T., Zou, S.-S., & Wu, A. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00175 · Cited by 110
“The UCHL1 gene mutations have been discovered to be related to familial PD and the oxidative inactivation of Uchl1 protein has been reported in PD and AD brains (Choi et al., 2004).”
BackgroundDeubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases
Liu, B., Ruan, J., Chen, M., Li, Z., Manjengwa, G. M., Schlüter, D., Song, W., & Wang, X. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01233-8 · Cited by 109
Carolan, B. J., Heguy, A., Harvey, B., Leopold, P. L., Ferris, B., & Crystal, R. G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2224 · Cited by 109
“A hereditary form of Parkinson’s disease has also been linked to an I93M mutation in the UCHL1 gene (45), consistent with a proposed role of UCHL1 in maintaining the balance of normal proteins within the cell (46, 47).”
BackgroundBustamante, H. A., González, A. E., Cerda-Troncoso, C., Shaughnessy, R., Otth, C., Soza, A., & Burgos, P. V. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00126 · Cited by 100
“…specific DUB ubiquitin carboxylterminal hydrolase L1 (UCH-L1)—one of the most abundant proteins in the brain—is downregulated in sporadic AD brains (Choi et al., 2004) and its activity is reduced in the hippocampus Frontiers in Cellular Neuroscience | www.frontiersin.org 6 May 2018 | Volume 12 |…”
BackgroundReversible Monoubiquitination Regulates the Parkinson Disease-associated Ubiquitin Hydrolase UCH-L1
Meray, R. K., & Lansbury, P. T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611153200 · Cited by 103
Shen, Y., Hua, L., Yeh, C.-K., Shen, L., Ying, M., Zhang, Z., Liu, G., Li, S., Chen, S., Chen, X., et al. (2020) · Theranostics · doi:10.7150/thno.44152 · Cited by 96
“It has been reported that intraneuronal Aβ can be degraded by ubiquitin-proteosome pathway [74], which has also been recognized to relate with the degradation of phosphorylated tau [75].”
BackgroundWang, K., Kobeissy, F. H., Shakkour, Z., & Tyndall, J. A. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.622 · Cited by 106
Graham, S. H., & Liu, H. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.011 · Cited by 94
“The aggregates also contain proteasome components and cytoskeletal elements associated with the UPP and are termed aggresomes (Choi et al., 2004).”
InfluentialZucchelli, S., Codrich, M., Marcuzzi, F., Pinto, M., Vilotti, S., Biagioli, M., Ferrer, I., & Gustincich, S. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq290 · Cited by 110
Role of ubiquitin–proteasome-mediated proteolysis in nervous system disease
Hegde, A. N., & Upadhya, S. C. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.07.006 · Cited by 96
“Full-length human UCHL1 appears to be a major target of oxidative damage in AD and PD brains, and the enzyme is extensively modified by carbonyl formation, methionine oxidation, and cysteine oxidation [99].”
Chemical and semisynthetic approaches to study and target deubiquitinases
Gopinath, P., Ohayon, S., Nawatha, M., & Brik, A. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00083e · Cited by 102
Presynaptic function in health and disease
Waites, C. L., & Garner, C. C. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.03.004 · Cited by 106
Aluise, C. D., Robinson, R. A. S., Cai, J., Pierce, W. M., Markesbery, W. R., & Butterfield, D. A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101083 · Cited by 94
“Furthermore, previous reports have shown a downregulation of UCHL1 in AD brain compared to controls [55]; here, we observe lower levels of this protein in MCI relative to both control and PCAD.”
Control of BACE1 degradation and APP processing by ubiquitin carboxyl‐terminal hydrolase L1
Zhang, M., Deng, Y., Luo, Y., Zhang, S., Zou, H., Cai, F., Wada, K., & Song, W. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07644.x · Cited by 92
“Interestingly, reduced UCHL1 expression was found in post-mortem brain tissue of AD patients, and the decreased level of UCHL1 was inversely proportional to neurofibrillary tangle numbers (Choi et al. 2004).”
BackgroundKabuta, T., Setsuie, R., Mitsui, T., Kinugawa, A., Sakurai, M., Aoki, S., Uchida, K., & Wada, K. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn037 · Cited by 100
“These results strongly suggest that carbonyl-modified UCH-L1 is also toxic to neurons and constitutes one of the causes of sporadic PD. Considering that UCH-L1 is abundant in the brain (5), and that UCH-L1 is a major target of carbonyl damage in PD brains ( 12 ), it is possible that carbonyl-modified UCH-L1 is the maj…”
BackgroundResultInfluentialProteomic research in psychiatry
Taurines, R., Dudley, E., Grassl, J., Warnke, A., Gerlach, M., Coogan, A. N., & Thome, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106931 · Cited by 92
Neurochemistry and the non-motor aspects of PD
Ferrer, I., López-Gonzalez, I., Carmona, M., Dalfó, E., Pujol, A., & Martínez, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.019 · Cited by 87
“In addition, DJ-1 in astrocytes modulates the innate immunity signaling (Cornejo Castro et al., 2010) and confers neuroprotection to neighboring neurons (Mullett and Hinkle, 2011).”
BackgroundWang, K., Yang, Z., Sarkis, G. A., Torres, I., & Raghavan, V. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1321635 · Cited by 92
An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes
Ristic, G., Tsou, W.-L., & Todi, S. V. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00072 · Cited by 88
Genetic contributions to Parkinson's disease
Huang, Y. M., Cheung, L., Rowe, D. B., & Halliday, G. M. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.04.007 · Cited by 110
“However, recent proteomic evidence reveals that full-length UCHL1 is a major target of oxidative damage and UCHL1 is downregulated in the brains of patients with either Alzheimer’s disease or PD [35].”
BackgroundUsing ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease
Caudle, W. M., Bammler, T. K., Lin, Y. S., Pan, S., & Zhang, J. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.54 · Cited by 99
The effects of oxidative stress on parkin and other E3 ligases
LaVoie, M. J., Cortese, G. P., Ostaszewski, B. L., & Schlossmacher, M. G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04911.x · Cited by 89
“The neuron-specific protein UCH-L1 has been shown to be oxidatively modified both in vitro and in vivo (Choi et al. 2004), making it an ideal control for the effects of H2O2.”
BackgroundNoncanonical transnitrosylation network contributes to synapse loss in Alzheimer’s disease
Nakamura, T., Oh, C.-K., Liao, L., Zhang, X., Lopez, K. M., Gibbs, D., Deal, A. K., Scott, H. R., Spencer, B., Masliah, E., et al. (2021) · Science · doi:10.1126/science.aaw0843 · Cited by 89
“Decreased Uch-L1 activity is observed in humanbrainswith AD aswell as in ADmouse models (28, 29).”
BackgroundMethodRole of lncRNAs in aging and age‐related diseases
He, J., Tu, C., & Liu, Y. (2018) · Aging Medicine · doi:10.1002/agm2.12030 · Cited by 91
An update on clinical proteomics in Alzheimer’s research
Korolainen, M. A., Nyman, T. A., Aittokallio, T., & Pirttilä, T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06558.x · Cited by 86
“2006c, 2007b), and UCH-L1 in frontal cortex (Choi et al. 2004; Muller et al. 2008) as well as increased levels of a-enolase in hippocampus (Schonberger et al.”
BackgroundSriram, K., Lin, G. X., Jefferson, A. M., Roberts, J. R., Wirth, O., Hayashi, Y., Krajnak, K., Soukup, J. M., Ghio, A. J., Reynolds, S. H., et al. (2010) · The FASEB Journal · doi:10.1096/fj.10-163964 · Cited by 94
Non-coding RNA in neural function, disease, and aging
Szafranski, K. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00087 · Cited by 85
“Interestingly, UCHL1 has also been demonstrated to be oxidatively inactivated in the brains of individuals with PD or AD (Choi et al., 2004; Barrachina et al., 2006).”
BackgroundCould Alzheimer’s Disease Originate in the Periphery and If So How So?
Morris, G., Berk, M., Maes, M., & Puri, B. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1092-y · Cited by 83
“This may induce a cascade of self-amplifying pathology as the hyperphosphorylation of tau and the formation of NFTs in the brains of AD patients results in an increased production of haem oxygenase-1 (HO-1) [372, 373] which provokes the release of Fe(II) [374], whichmay exacerbate ROS production via Fenton chemistry […”
BackgroundInfluentialSultana, R., & Butterfield, D. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129018 · Cited by 83
“These techniques form the basis of the methodology needed to further examine the role of oxidative modifications of specific brain proteins in AD pathogenesis and have led to the development and use of redox proteomic [44] techniques to identify carbonylated brain proteins in AD [41, 42, 49].”
S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation
Kumar, R., Jangir, D. K., Verma, G., Shekhar, S., Hanpude, P., Kumar, S., Kumari, R., Singh, N., Sarovar Bhavesh, N., Ranjan Jana, N., et al. (2017) · Scientific Reports · doi:10.1038/srep44558 · Cited by 82
Protein S-nitrosylation and oxidation contribute to protein misfolding in neurodegeneration
Nakamura, T., Oh, C.-K., Zhang, X., & Lipton, S. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.07.002 · Cited by 88
Thiol-Redox Signaling, Dopaminergic Cell Death, and Parkinson's Disease
Garcia-Garcia, A., Zavala-Flores, L., Rodriguez-Rocha, H., & Franco, R. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4501 · Cited by 83
“MPP + Sulfinic/sulfonic acid DJ-1 Irreversible (4, 23) Parkin (120) Sulfonic acid Parkin Irreversible (120) S-nitrosylation Parkin Reversible (35, 192) PRDX2 Reversible (55) S-nitrosylation XIAP Reversible (172) Glutathionylation IDPM Reversible (97) Rotenone S-nitrosylation Parkin Reversible (192) PDI Reversible (173…”
Methods for proteomics in neuroscience
Tannu, N. S., & Hemby, S. E. (2006) · Progress in brain research · doi:10.1016/s0079-6123(06)58003-3 · Cited by 86
Garcia‐Esparcia, P., Llorens, F., Carmona, M., & Ferrer, I. (2014) · Brain Pathology · doi:10.1111/bpa.12137 · Cited by 80
Koharudin, L. M. I., Liu, H., Maio, R. D., Kodali, R. B., Graham, S. H., & Gronenborn, A. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002295107 · Cited by 80
“Uchida K, Shibata T (2008) 15-Deoxy-Delta(12,14)-prostaglandin J2: An electrophilic trigger of cellular responses.”
BackgroundAnalysis of a membrane‐enriched proteome from postmortem human brain tissue in Alzheimer's disease
Donovan, L. E., Higginbotham, L., Dammer, E. B., Gearing, M., Rees, H. D., Xia, Q., Duong, D. M., Seyfried, N. T., Lah, J. J., & Levey, A. I. (2012) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201100068 · Cited by 82
Self-citationLack of glutathione peroxidase-1 exacerbates Aβ-mediated neurotoxicity in cortical neurons
Crack, P. J., Cimdins, K., Ali, U., Hertzog, P. J., & Iannello, R. C. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0352-y · Cited by 83
“…generation of free radicals by Ab in aqueous solution (Lynch et al., 2000; Monji et al., 2001), and the increase in protein carboxyl formation following Ab exposure (Garzon-Rodriguez et al., 2000; Choi et al., 2004), have implicated oxidative stress as a central component of in vitro Ab toxicity.”
BackgroundThe Effect of Parkinson's-Disease-Associated Mutations on the Deubiquitinating Enzyme UCH-L1
Andersson, F. I., Werrell, E. F., McMorran, L. M., Crone, W. J. K., Das, C., Hsu, S. D., & Jackson, S. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.12.029 · Cited by 88
“Such chemical modification of UCH-L1 has also been associated with a number of neurodegenerative diseases, including PD and AD.(16)”
InfluentialMeyer‐Schwesinger, C., Meyer, T., Münster, S., Klug, P., Saleem, M. A., Helmchen, U. M., & Stahl, R. (2008) · The Journal of Pathology · doi:10.1002/path.2446 · Cited by 78
Mrozik, K. M., Zilm, P. S., Bagley, C. J., Hack, S., Hoffmann, P., Gronthos, S., & Bartold, P. M. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0446 · Cited by 84
Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease
Ferrer, I. (2011) · Parkinson's Disease · doi:10.4061/2011/708404 · Cited by 71
Adav, S. S., & Sze, S. K. (2016) · Molecular Brain · doi:10.1186/s13041-016-0272-9 · Cited by 70
Protein Aggregation Mechanisms in Synucleinopathies: Commonalities and Differences
Beyer, K., & Ariza, A. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181587d64 · Cited by 72
“An important protein target of oxidative damage is Cu,Zn-superoxide dismutase, a key antioxidant enzyme whose function is altered by oxidative modifications (74).”
BackgroundIn vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury
Gorgoraptis, N., Li, L. M., Whittington, A., Zimmerman, K. A., Maclean, L. M., McLeod, C., Ross, E., Heslegrave, A., Zetterberg, H., Passchier, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1993 · Cited by 75
“Dysfunction of UCH-L1 is implicated in a number of neurodegenerative diseases (43, 44), and UCH-L1 is found within misfolded protein aggregates, including neurofibrillary tangles (45).”
BackgroundSelf-citationProtein expression profile in the striatum of acute methamphetamine-treated rats
Iwazaki, T., McGregor, I. S., & Matsumoto, I. (2006) · Brain Research · doi:10.1016/j.brainres.2006.04.052 · Cited by 74
Proteomic approaches in brain research and neuropharmacology
Vercauteren, F., Bergeron, J. J. M., Vandesande, F., Arckens, L., & Quirion, R. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.039 · Cited by 84
Oxidative protein damage and the proteasome
Grimm, S., Höhn, A., & Grune, T. (2010) · Amino Acids · doi:10.1007/s00726-010-0646-8 · Cited by 77
“Under oxidative stress, UCH-L1 is oxidatively modified and the hydrolase activity is decreased (Choi et al. 2004).”
BackgroundDiagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach
van Dijk, K. D., Teunissen, C. E., Drukarch, B., Jimenez, C. R., Groenewegen, H. J., Berendse, H. W., & van de Berg, W. D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.04.020 · Cited by 72
“Indeed, in the substantia nigra of PD patients increased amounts of oxidatively modified proteins have been observed, such as oxidatively modified UCH-L1 (Choi et al., 2004) and nitrated α-synuclein (Giasson et al.”
Hong, X., Liu, J., Zhu, G., Zhuang, Y., Suo, H., Wang, P., Huang, D., Xu, J., Huang, Y., Yu, M., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt501 · Cited by 69
“These data supplement findings describing that the E3 ligase UCH-L1 is down-regulated in AD brains (36) and that transduction of UCH-L1 protein restores synaptic function in APP/PS1 mice (37).”
ResultAlzheimer’s Disease and ncRNAs
Maoz, R., Garfinkel, B. P., & Soreq, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_18 · Cited by 78
Takami, Y., Nakagami, H., Morishita, R., Katsuya, T., Cui, T., Ichikawa, T., Saito, Y., Hayashi, H., Kikuchi, Y., Nishikawa, T., et al. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.142505 · Cited by 73
Sultana, R., Perluigi, M., & Butterfield, D. A. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.09.024 · Cited by 80
Ho Kim, J., Franck, J., Kang, T., Heinsen, H., Ravid, R., Ferrer, I., Hee Cheon, M., Lee, J.-Y., Shin Yoo, J., Steinbusch, H. W., et al. (2015) · Scientific Reports · doi:10.1038/srep11138 · Cited by 68
“In contrast to the function of YWHAZ, UCHL1 was previously reported 28 to play an important role in preventing neurofibrillary tangle formation by de-ubiquitination of phosphorylated tau.”
Lipton, S. A., Gu, Z., & Nakamura, T. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82001-0 · Cited by 80
Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies
Barrachina, M., Castaño, E., Dalfó, E., Maes, T., Buesa, C., & Ferrer, I. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.005 · Cited by 69
“However, other studies have shown no UCHL-1 immunostaining in PD although UCHL-1 immunoreactivity was present in neurons with neurofibrillary tangles in AD (Choi et al., 2004).”
BackgroundCostes, S., Gurlo, T., Rivera, J. F., & Butler, P. C. (2014) · Autophagy · doi:10.4161/auto.28478 · Cited by 70
“In neurons, UCHL1 may be modified by oxidative stress, leading to an alteration of its function.(19,44) Besides these acquired alterations/modifications, UCHL1 has been described as a Parkinson disease susceptibility gene.”
BackgroundSUN, F., KANTHASAMY, A. G., ANANTHARAM, V., & KANTHASAMY, A. G. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.001 · Cited by 73
Sakurai, M., Sekiguchi, M., Zushida, K., Yamada, K., Nagamine, S., Kabuta, T., & Wada, K. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06047.x · Cited by 75
“L1 is involved in idiopathic Alzheimer’s disease (AD) and Parkinson’s disease (PD): (i) UCH-L1 is down-regulated in idiopathic AD and PD (Choi et al., 2004), and in an AD model mouse (Gong et al.”
BackgroundInfluentialEffects of UCH‐L1 on α‐synuclein over‐expression mouse model of Parkinson’s disease
Yasuda, T., Nihira, T., Ren, Y., Cao, X., Wada, K., Setsuie, R., Kabuta, T., Wada, K., Hattori, N., Mizuno, Y., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05827.x · Cited by 66
“UCH-L1 is also reported to undergo oxidative modification in the brains of patients with PD and Alzheimer’s disease (Choi et al. 2004).”
BackgroundZhao, Z., Wu, L., Xiong, R., Wang, L.-L., Zhang, B., Wang, C., Li, H., Liang, L., & Chen, S. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.06.013 · Cited by 71
Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity
Perez, F. A., Curtis, W. R., & Palmiter, R. D. (2005) · BMC Neuroscience · doi:10.1186/1471-2202-6-71 · Cited by 67
“Nevertheless, we cannot rule out the possibility that differences in oxidation between WT and KO mice are limited to a few specific proteins [52].”
BackgroundGuglielmotto, M., Monteleone, D., Boido, M., Piras, A., Giliberto, L., Borghi, R., Vercelli, A., Fornaro, M., Tabaton, M., & Tamagno, E. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00854.x · Cited by 65
“Several lines of evidence suggest that the activity of Uch-L1 is downregulated in AD brain (Pasinetti, 2001; Choi et al., 2004).”
BackgroundJara, J. H., Genç, B., Cox, G. A., Bohn, M. C., Roos, R. P., Macklis, J. D., Ulupınar, E., & Özdinler, P. H. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhu318 · Cited by 71
“Interestingly, reduced UCHL1 levels are reported in PD, AD, and ALS patients (Choi et al. 2004; Lombardino et al. 2005; Barrachina et al. 2006; Lederer et al. 2007).”
BackgroundTan, M. S., Cheah, P., Chin, A., Looi, L., & Chang, S. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104947 · Cited by 69
Shen, H., Sikorska, M., Leblanc, J. E., Walker, P. R., & Liu, Q. Y. (2006) · APOPTOSIS · doi:10.1007/s10495-006-6303-8 · Cited by 66
Sultana, R., Baglioni, M., Cecchetti, R., Cai, J., Klein, J. B., Bastiani, P., Ruggiero, C., Mecocci, P., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.001 · Cited by 64
“Previous studies from our laboratory and others showed alteration of these proteins in AD and MCI brain [51] [52] [53] [54] [55] [56].”
Transcriptome profiling in neurodegenerative disease
Courtney, E., Kornfeld, S., Janitz, K., & Janitz, M. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.08.018 · Cited by 71
From Junk to Function: LncRNAs in CNS Health and Disease
Policarpo, R., Sierksma, A. S. R., Strooper, B. D., & d’Ydewalle, C. V. O. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.714768 · Cited by 70
“UCHL1 gene variants are associated with susceptibility to PD (Ying et al., 2015), and oxidative modifications and downregulation of UCHL1 protein are observed in sporadic cases of both AD and PD patients (Choi et al., 2004).”
BackgroundUbiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases
Hwang, J., Lee, A., & Kho, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095053 · Cited by 69
Proteomics of protein post-translational modifications implicated in neurodegeneration
Ren, R.-J., Dammer, E. B., Wang, G., Seyfried, N. T., & Levey, A. I. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-23 · Cited by 63
“A number of studies [63-73] utilize parallel detection by, for example, two-dimensional polyacrylamide (2D-PAGE) oxyblot analysis, in which carbonyl moieties (aldehydes and especially ketones, both of which normally are not present on proteins) are reacted with dinitrophenylhydrazine to form dinitrophenylhydrazone (DN…”
Self-citationJang, Y., Pletniková, O., Troncoso, J. C., Pantelyat, A. Y., Dawson, T. M., Rosenthal, L. S., & Na, C. H. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100452 · Cited by 72
“(58, 59) reported altered expression of ubiquitin carboxyl-terminal hydrolase L1 and oxidative damage of DJ1 in the PD brain.”
Protein Carbonyl and the Methionine Sulfoxide Reductase System
Moskovitz, J., & Oien, D. B. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2809 · Cited by 66
“A significant eight- and 10-fold increase in the specific oxidation level of full-length UCH-L1 was observed in idiopathic AD and PD brains, respectively, compared with age-matched controls (18).”
Ubiquitination and cysteine nitrosylation during aging and Alzheimer's disease
Riederer, I. M., Schiffrin, M., Kövari, E., Bouras, C., & Riederer, B. M. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.04.018 · Cited by 60
The Role of Deubiquitinating Enzymes in Synaptic Function and Nervous System Diseases
Kowalski, J. R., & Juo, P. (2012) · Neural Plasticity · doi:10.1155/2012/892749 · Cited by 66
Petrov, D., & Žagrović, B. (2011) · Journal of the American Chemical Society · doi:10.1021/ja110577e · Cited by 61
Skorobogatko, Y. V., Deuso, J., Adolf-Bergfoyle, J., Nowak, M. G., Gong, Y., Lippa, C. F., & Vosseller, K. (2010) · Amino Acids · doi:10.1007/s00726-010-0645-9 · Cited by 63
Molecular mechanisms of nitrosative stress-mediated protein misfolding in neurodegenerative diseases
Nakamura, T., & Lipton, S. A. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6525-0 · Cited by 67
Liu, H., Li, W., Ahmad, M., Miller, T. M., Rose, M. E., Poloyac, S. M., Uechi, G. T., Balasubramani, M., Hickey, R. W., & Graham, S. H. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.09.020 · Cited by 64
“UCH-L1 is amajor oxidative damage target inbrain and that it can be modified by a variety of reagents under different pathological conditions (Choi et al., 2004).”
BackgroundÖhrfelt, A., Johansson, P., Wallin, A., Andréasson, U., Zetterberg, H., Blennow, K., & Svensson, J. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000447239 · Cited by 63
Ciavardelli, D., Silvestri, E., Viscovo, A. D., Bomba, M., Gregorio, D. D., Moreno, M., Ilio, C. D., Goglia, F., Canzoniero, L. M. T., & Sensi, S. L. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.68 · Cited by 57
“Interestingly, UCHL1 has been found to be decreased and its level is inversely proportional to the number of NFTs in AD brain.(34) UCHL1 is also required for normal synaptic function and rescues Ab-related synaptic dysfunction in transgenic AD mice.”
BackgroundYu, Y., Wu, J., Fan, Y., Lv, Z., Guo, X., Zhao, C. L., Zhou, R., Zhang, Z., Wang, F., Xiao, M., et al. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800273-mcp200 · Cited by 63
“UCHL1 levels are low (37), or its function is compromised (38,”
BackgroundUCH‐L1 promotes invasion of breast cancer cells through activating Akt signaling pathway
Luo, Y., He, J., Yang, C., Orange, M., Ren, X., Blair, N. F., Tan, T., Yang, J., & Zhu, H. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26232 · Cited by 58
The potential roles of deubiquitinating enzymes in brain diseases
Lim, K., Joo, J., & Baek, K. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101088 · Cited by 61
“UCHL1 is a well-known protein that is associated with both AD- and PD (Choi et al., 2004).”
BackgroundProteomic changes in the crucian carp brain during exposure to anoxia
Smith, R. W. P., Cash, P., Ellefsen, S., & Nilsson, G. (2009) · PROTEOMICS · doi:10.1002/pmic.200800662 · Cited by 57
Genetic causes of Parkinson?s disease: UCHL-1
Healy, D. G., Abou‐Sleiman, P. M., & Wood, N. W. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0917-3 · Cited by 57
“Another study involving the use of post-mortem PD brain has shown that UCHL-1 undergoes differential oxidative damage compared with that of age-matched control brain (Choi et al. 2004).”
BackgroundInfluentialMcKeon, J. E., Di, S., Li, L., & Chin, L. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1781-2 · Cited by 60
“This apparent discrepancy could be reconciled by the fact that only the soluble levels of UCHL1 protein were measured in our previous study [22] and that UCH-L1 protein was also found to aggregate with Parkin-mediated K63-polyubiquitination targets ubiquitin 1821”
InfluentialSelf-citationDelirium and A lzheimer disease: A proposed model for shared pathophysiology
Fong, T. G., Vasunilashorn, S. M., Libermann, T. A., Marcantonio, E. R., & Inouye, S. K. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5088 · Cited by 63
“Postmortem studies of brains from patients with sporadic AD show a downregulation of UCH‐L1.(46) In TBI, UCH‐L1 levels are increased within 1 hour.”
BackgroundNRF2 Activation and Downstream Effects: Focus on Parkinson’s Disease and Brain Angiotensin
Parga, J. A., Rodriguez-Perez, A. I., García-Garrote, M., Rodríguez‐Pallares, J., & Labandeira-García, J. L. (2021) · Antioxidants · doi:10.3390/antiox10111649 · Cited by 61
“PARK5 gene, UCHL-1 (Ubiquitin Carboxyl-terminal Hydrolase L1), is a deubiquitinating enzyme that is affected by oxidative stress in PD [114].”
BackgroundBerg, D. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9346-5 · Cited by 63
“proteasome system like UCH-L1 [89, 90, 83, 84].”
Bifsha, P., Landry, K., ASHMARINA, L. I., Durand, S., Seyrantepe, V., Trudel, S., Quiniou, C., Chemtob, S., Xu, Y., Gravel, R. A., et al. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402013 · Cited by 57
Docosahexaenoic Acid Reduces Amyloid-β Induced Toxicity in Cells of the Neurovascular Unit
Veszelka, S., Tóth, A. E., Walter, F. R., Datki, Z., Mózes, E., Fülöp, L., Bozsó, Z., Hellinger, É., Vastag, M., Orsolits, B., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-120163 · Cited by 51
“ing postmortem analysis [77].”
Metadata
- Authors
- Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L.
- Affiliations
- Emory University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Li, Lian
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 279
- Issue
- 13
- Pages
- 13256-13264
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2169393803
- Cited by
- 568
- References
- 38
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 20 · 2021: 36 · 2020: 16 · 2019: 16 · 2018: 22 · 2017: 28 · 2016: 24 · 2015: 26 · 2014: 34 · 2013: 29 · 2012: 30
- FWCI
- 19.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6057 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG010130, AG-10130, AG021489, R01AG021489)
- National Cancer Institute (P30CA054174, CA-54174)
- National Institute of Neurological Disorders and Stroke (NS-047199, R01NS047199)
- National Institute of Environmental Health Sciences (ES-12068, U54ES012068)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- UCHL1, Parkinson's disease, Alzheimer's disease, protein oxidation, carbonylation, methionine oxidation, cysteine oxidation, deubiquitination, neurofibrillary tangles, protein downregulation, brain proteome
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Brain, Chromatography, High Pressure Liquid, Coloring Agents, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Molecular Sequence Data, Mutation, Oxygen, Parkinson Disease, Mass Spectrometry, Trypsin, Immunoblotting, Electrophoresis, Gel, Two-Dimensional, Down-Regulation, Sequence Homology, Amino Acid, Protein Structure, Tertiary, Oxidative Stress, Protein Isoforms, Proteome, Ubiquitin Thiolesterase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.